A Guide To Drug-Drug Interactions In Podiatry

Author(s): 
Robert G. Smith, DPM, MSc, RPh, CPed

   Published clinical evidence does exist for many of the reported drug-drug interactions that cause serious adverse reactions. Therefore, podiatric physicians should consider the results of published literature as well as their own clinical experience when making decisions on the potential for drug interactions in their patient population.

   Dr. Smith is in private practice at Shoe String Podiatry in Ormond Beach, Fla.

References

1. Prescription Drug Trends Fact Sheet. Kaiser Family Foundations, 2008. Available at www.kff.org/rxdrugs/upload/3057_07.pdf .

2. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: US prescription drug data for 2007-2008. NCHS data brief, no 42. National Center for Health Statistics, Hyattsville, MD, 2010.

3. Manasse HR. Medication use in an imperfect world: drug misadventuring as an issue of public policy, Part 1. Am J Hosp Pharm. 1989; 46(5):929-944.

4. Manasse HR. Toward defining and applying a higher standard of quality for medication use in United States. Am J Health-Syst Pharm. 1995; 52(4):374-379.

5. Kelly ON. The role of pharmacoepidemiology and expert testimony. In (O’Donnell JT, ed.) Drug Injury: Liability, analysis and prevention, 2nd edition. Lawyers & Judges Publishing Co., Inc., Tucson, AZ, 2005.

6. Benet LZ, Kroetz DL, and Sheiner LB. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In (Hardman JG, Limbird LE, eds.) Goodman and Gilman’s The pharmacological basis of therapeutics. McGraw Hill, New York, 1996, pp. 3-27.

7. Bauer LA. Clinical pharmacokinetics and pharmacodynamics. In
(Dipro JT, ed.) Pharmacotherapy: a pathophysiologic approach. Appleton & Lange, Stamford, CT, 1999, pp. 21-30.

8. Hansten PD, Horn JR. Drug interaction mechanisms: enzyme induction. In Hansten and Horn’s Drug Interactions Analysis and Management. Facts and Comparison, St. Louis, MO, 2003, pp. 1-15.

9. Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharm. 2006; 1(1):5-20.

10. Nelson DR, Koymans L, Kamataki T et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6(1):1-42.
11. Streetman DS. Metabolic differences and pharmacogenetics: Implications for anesthesia. Anesthesia Today. 2004; 14(3):12-20.

12. Koch I, Weil R, Woldold R, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispo. 2002; 30(10):1008-1114.

13. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinetics. 2009; 48(3):143-157.

14. Horn JR, Hansten PD. The ignorance of certainty-“facts” sometimes aren’t. Pharmacy Times, 2005. Available at www.hanstenandhorn.com/hh-article09-05.pdf. Accessed May 1, 2011.

15. McInnes GT, Brodie MJ. Drug interactions that matter. A critical reappraisal. Drugs. 1988; 36(1):83-110.

16. Brüggemann RJM, Alffenaar JC, Blijlevens NM et al. Clinical relevance of the pharmaokinetic interactions of azole antifungal drugs with other coadministered agents: Reviews of anti-infective agents. Clin Infect Dis. 2009; 48(10):1441-1458.

17. Yu DT. Peterson JF, Seger DL, et al. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf. 2005; 14(11):755-767.

18. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis. 1990; 12(3):S327-S333.

19. Angirasa AK, Koch AZ. P-glycoprotein as the mediator of itraconazole-digoxin interaction. J Am Podiatr Med Assoc. 2002; 92(8):471-472.

20. Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci. 2010; 113(4):315-324.

21. Schelleman H, Bilker WB, Brensinger CM et al. Warfarin with fluroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther. 2008; 84(5):581-588.

Add new comment